Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.61 |
| ▸ | RAB9A | P51151 | 7/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.61 |
| ▸ | NPC1 | O15118 | 6/20 | 0.61 |
| ▸ | APP | P05067 | 5/20 | 0.61 |
| ▸ | GLA | P06280 | 5/20 | 0.61 |
| ▸ | GAA | P10253 | 5/20 | 0.61 |
| ▸ | SNCA | P37840 | 1/20 | 0.58 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.54 |
| ▸ | CDK2 | P24941 | 1/20 | 0.54 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.54 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | CASP3 | P42574 | 1/20 | 0.50 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.50 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25028306 | 0.83 | KDM4E (0.43) | MAPTRAB9AKDM4ENPC1APP | |
| SCHEMBL12422217 | 0.82 | MAPT (0.81) | MAPTRAB9AKDM4ENPC1APP | |
| SCHEMBL1637646 | 0.81 | APP (0.58) | MAPTRAB9AKDM4ENPC1APP | |
| SCHEMBL1638288 | 0.81 | APP (0.61) | MAPTKDM4EAPPCCNE1CDK2 | |
| SCHEMBL13444809 | 0.81 | MAPT (0.69) | MAPTRAB9AKDM4ENPC1APP | |
| SCHEMBL3190615 | 0.81 | MAPT (0.69) | MAPTRAB9AKDM4ENPC1APP | |
| SCHEMBL507097 | 0.79 | MAPT (0.71) | MAPTRAB9AKDM4ENPC1APP | |
| SCHEMBL5164826 | 0.79 | APP (0.43) | MAPTRAB9AKDM4ENPC1APP | |
| SCHEMBL1638045 | 0.79 | CDK5 (0.60) | MAPTRAB9AKDM4ENPC1APP | |
| SCHEMBL14111242 | 0.78 | MAPT (0.65) | MAPTRAB9AKDM4ENPC1APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098292-A1 | New Compounds Useful for Treating CNS Disorders | ASTRAZENECA AB (SE) | 2011-04-28 | — | — | US | claimed |
| CN-1980922-A | New compounds useful for treating CNS disorders | ASTRAZENECA AB (SE) | 2007-06-13 | — | — | CN | claimed |
| EP-1765815-A2 | NEW COMPOUNDS USEFUL FOR TREATING CNS DISORDERS | AstraZeneca AB (SE) | 2007-03-28 | — | — | EP | claimed |
| WO-2006004507-A2 | NEW BENZOTHIAZOLE DERIVATIVES USEFUL FOR TREATING CNS DISORDERS | ASTRAZENECA AB (SE) | 2006-01-12 | — | — | WO | claimed |
| US-20110098292-A1 | New Compounds Useful for Treating CNS Disorders | ASTRAZENECA AB (SE) | 2011-04-28 | — | — | US | disclosed |
| CN-1980922-A | New compounds useful for treating CNS disorders | ASTRAZENECA AB (SE) | 2007-06-13 | — | — | CN | disclosed |
| EP-1765815-A2 | NEW COMPOUNDS USEFUL FOR TREATING CNS DISORDERS | AstraZeneca AB (SE) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006004507-A2 | NEW BENZOTHIAZOLE DERIVATIVES USEFUL FOR TREATING CNS DISORDERS | ASTRAZENECA AB (SE) | 2006-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098292-A1 | New Compounds Useful for Treating CNS Disorders | SLC18A2, PMP22, GAP43 | MAPT 96/4885RAB9A 726/4885KDM4E 3850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.